ADHD drug maker suing DEA over ‘effectively shutting down’ manufacturing
OMAHA, Neb. (WOWT) - During an ongoing national shortage for drugs used to treat attention-deficit-hyperactivity disorder (ADHD), one manufacturer is suing the federal government. A New York-based law firm representing Ascent Pharmaceuticals, Inc. said the Drug Enforcement Administration is keeping its client from manufacturing generic prescriptions to treat ADHD.
Other Articles in this Edition
Narcolepsy Drug Might Be New Treatment Option for ADHD
The A.D.H.D. Drug Shortage Is Causing Real Pain (Opinion)
ADHD Appears Underdiagnosed in Patients at a Pediatric Headache Clinic
DEA extends pandemic telehealth rules for prescribing controlled substances
ADHD drug maker suing DEA over ‘effectively shutting down’ manufacturing
3 Reasons Why More Students Are in Special Education
New research finds greater continuity of psychotherapy after shift to telehealth
Report: Impacts of climate change threaten children’s mental health starting before birth
Navigating Challenges in Treatment of Attention Deficit Hyperactivity Disorder (ADHD)